Prosecution Insights
Last updated: April 19, 2026
Application No. 17/311,600

VERY LONG CHAIN FATTY ACID COMPOSITIONS

Final Rejection §101
Filed
Jun 07, 2021
Examiner
WHITE, DAWANNA SHAR-DAY
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Epax Norway AS
OA Round
5 (Final)
61%
Grant Probability
Moderate
6-7
OA Rounds
3y 9m
To Grant
92%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
62 granted / 102 resolved
+0.8% vs TC avg
Strong +31% interview lift
Without
With
+30.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
44 currently pending
Career history
146
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
34.0%
-6.0% vs TC avg
§102
13.6%
-26.4% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 102 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . All previous objections and rejections not reiterated herein were overcome by amendments to the claims and specifications, filed January 20th, 2026 have been fully considered and found persuasive. As such the objections and rejections not reiterated herein have been withdrawn. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1 – 5, 7, 9, 12 – 17, 22, 27 and 32 – 36 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a natural phenomenon without significantly more. The claims recite an enriched composition comprising a fatty acid mixture and at least one additive, wherein the fatty acid mixture comprises at least 4.0 % by weight of very long chain monounsaturated fatty acids and at least 1.0 % by weight of very long chain polyunsaturated fatty acids, wherein the very long chain monounsaturated fatty acids and the very long chain polyunsaturated fatty acids have a chain length of 24 carbon atoms or more, and the fatty acid mixture comprises at least 1% by weight of very long chain monounsaturated fatty acids with chain length of 26 carbon atoms or more, wherein the fatty acids are derived from natural oils. Moreover the claims further recite that the at least one additive is selected from the group of solvents, carriers, viscosity modifiers, diluents, binders, sweeteners, aromas, pH modifiers, antioxidants, extenders, humectants, disintegrating agents, solution-retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, colouring agents, pigments, thickeners, stabilisers, glossing agents, gelling agents, dispersing agents, salts, oils, waxes, polymers, silicone compounds, biogenic agents, film formers, tonicity agents, emulsifiers, surfactants, buffers, inorganic and organic sunscreens, anti-inflammatory agents, free radical scavengers, moisturizers, vitamins, enzymes, and preservatives. However, as stated in the instant specification solvents and carriers includes water and ethanol (instant specification page 19 line 7). Additionally, the instant specification fails to limit, the at least one additive, to none natural forms. Each of these elements exists in nature, for example, the instant specification teach VLCPUFAs and VLCMUFAs are occur naturally in the bodies of mammals (page 2 lines 26 – 34) natural product versions can be selected. Additionally, the state of the art of Murphy et. al. ((1988), Biosynthesis of very long chain monounsaturated fatty acids by subcellular fractions of developing seeds, FEBS Letters, 230, 101-104; cited in the office action dated February 14th, 2025) teach that very long chain monounsaturated fatty acids, nervonic and cis-tetracosenoic acid (24: 1), are major constituents of certain seed oils (page 101 column 1 paragraph 1). Moreover, the state of the art of Carmona-Antonanzas et.al. ((2011), Biosynthesis of very long-chain fatty acids (C > 24) in Atlantic salmon: Cloning, functional characterisation, and tissue distribution of an Elovl4 elongase, Comparative Biochemistry and Physiology, Part B, 159, 122-129; cited in the office action dated February 14th, 2025) teach that very long-chain fatty acids (VLC-FA) are found in most animals and constitute a group of fatty acids (FA) with chain numbers normally ranging from C26 to C40 that can be saturated, monounsaturated or polyunsaturated (page 122 column 1 paragraph 1). Furthermore, Carmona-Antonanzas et.al. teach that the relative low abundance of VLC-FA compared to shorter chain FA (≤C24) and the difficulty of their analysis has hindered investigation of the functions and metabolism of VLC-FA (page 122 column 1 paragraph 1). Moreover, there is no indication in the specification that the claimed components within the composition have any characteristics (structural, functional, or otherwise) that are different from the naturally occurring components. Thus, the elements in the composition do not have markedly different characteristics from their natural counterparts in their natural state, and are “product of nature” exceptions. Accordingly, the claim is directed to a judicial exception. This judicial exception is not integrated into a practical application because the claims by nature do not recite any elements in addition to the naturally occurring products. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the prior art teach both VLCPUFAs and VLCMUFAs as naturally products. Hence, the claims do not amount to significantly more because they do not recite any elements in addition to the naturally occurring products. The applicant is advised that in order to overcome the rejection, applicant could and demonstrate that the combination of VLCPUFAs and VLCMUFAs as claimed has some characteristic that makes it markedly different from the natural counterparts. Response to Arguments Applicant's arguments and claim amendments filed January 20th, 2026, see applicants remark’s pages 7 – 9, have been fully considered but they are not persuasive. Applicants has amended the claims to include the recitation of, “and at least one additive,” and the applicant has stated that, “and at least one additive,” was included to clarify that the claimed composition as not naturally occurring (see applicant’s remarks page 7 paragraph 2). Additionally, the applicants argues that the enriched purified compositions exhibited at least five markedly different characteristics which include appearance, low oxidation parameters/enhanced stability, low cholesterol content, low environmental pollutants, and reduced order profile that distinguished it from any natural oil (see applicant’s remarks pages 8 paragraph 2). The examiner continues to contends that the markedly different characteristics of appearance, low oxidation parameters/enhanced stability, low cholesterol content, low environmental pollutants, and reduced order profile are the result of the method of preparation (withdrawn instant claims 28 – 31) and not of the composition itself. Additionally, as stated in the rejection, claim 1 has been amended to include the “at least one additive;” however, as defined in the specification the recitation can still include naturally derived additives such as ethanol and water. Likewise aloe vera gel/ or marshmallow root which are both natural products that are lubricants which are not excluded. Thus the limitation of “at least one additive” fails to overcome the 101 rejection of the instant claims. Thus there is no difference between the claimed and naturally occurring very long chain fatty acids, the claimed very long chain fatty acids does not have markedly different characteristics from what occurs in nature, and thus is a “product of nature” exception. Accordingly, the claim is directed to an exception (Step 2A: YES). Because the claim does not include any additional features that could add significantly more to the exception (Step 2B: NO), the claim does not qualify as eligible subject matter, and should be rejected under 35 U.S.C. § 101. Conclusion Claims 1 – 5, 7, 9, 12 – 17, 22, 27, and 32 – 36 are rejected. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAWANNA S WHITE whose telephone number is (703)756-4687. The examiner can normally be reached 7:00 am - 5:00 pm [EST] M - Th. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on 571-270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAWANNA SHAR-DAY WHITE/Examiner, Art Unit 1627 /JULIET C SWITZER/Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

Jun 07, 2021
Application Filed
Jun 27, 2024
Non-Final Rejection — §101
Oct 02, 2024
Response Filed
Feb 10, 2025
Non-Final Rejection — §101
May 14, 2025
Response Filed
May 27, 2025
Final Rejection — §101
Aug 29, 2025
Request for Continued Examination
Sep 05, 2025
Response after Non-Final Action
Oct 16, 2025
Non-Final Rejection — §101
Jan 20, 2026
Response Filed
Feb 12, 2026
Final Rejection — §101
Mar 31, 2026
Interview Requested
Apr 08, 2026
Applicant Interview (Telephonic)
Apr 08, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600725
SELECTIVE GRP94 INHIBITORS AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12582646
METHOD FOR TREATING DRUG OR ALCOHOL DEPENDENCY
2y 5m to grant Granted Mar 24, 2026
Patent 12582624
CO-CRYSTAL OF GABAPENTIN, KETOPROFEN AND LYSINE, PHARMACEUTICAL COMPOSITIONS AND THEIR MEDICAL USE
2y 5m to grant Granted Mar 24, 2026
Patent 12576015
ANTIMICROBIAL MIXTURE CONTAINING 4-(3-ETHOXY-4-HYDROXYPHENYL)BUTAN-2-ONE AND AN ALCOHOL COMPOUND, AND COSMETIC COMPOSITION CONTAINING SAME
2y 5m to grant Granted Mar 17, 2026
Patent 12569422
COMPOSITION AND METHOD OF INHIBITING CORTISONE REDUCTASE BY APPLYING IT TO THE SKIN
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

6-7
Expected OA Rounds
61%
Grant Probability
92%
With Interview (+30.8%)
3y 9m
Median Time to Grant
High
PTA Risk
Based on 102 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month